Investor Alert

Market Pulse Archives

Oct. 28, 2021, 6:31 a.m. EDT

Coronavirus tally: Global cases of COVID-19 top 245 million and study finds cheap antidepressant has promise as treatment

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)

or Cancel Already have a watchlist? Log In

By Ciara Linnane


The global tally for the coronavirus-borne illness climbed above 245 million on Thursday, while the death toll edged above 4.97 million, according to data aggregated by Johns Hopkins University . The U.S. continues to lead the world with a total of 45.7 million cases and 741,235 deaths. The U.S. is averaging about 1,400 deaths a day, according to a New York Times tracker, although cases and hospitalizations are declining. A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus, the Associated Press reported. Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies. They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for World Health Organization backing. The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's /zigman2/quotes/209956077/composite MRK -1.10% experimental antiviral pill for COVID-19 is about $700 per course. India is second by cases after the U.S. at 34.2 million and has suffered 456,386 deaths. Brazil has second highest death toll at 606,679 and 21.7 million cases. In Europe, Russia has the most fatalities at 230,786 deaths, followed by the U.K. at 140,462.

$ 111.07
-1.23 -1.10%
Volume: 6.38M
May 26, 2023 4:00p
P/E Ratio
Dividend Yield
Market Cap
$281.83 billion
Rev. per Employee

Get news alerts on Merck & Co. Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.